Dermapharm Value Stock - Dividend - Research Selection
Market price: 67,40 EUR
Dermapharm Holding Fundamental data and company key figures of the share
|Annual reports in EUR|
|Net operating cash flow||131.098.000|
|Free cash flow||90.302.000|
|Liabilities & Shareholders equity||1.224.400.000|
|Diluted shares outstanding||53.840.000|
✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!
How our site works ...
✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe
Price for monthly subscription $ 19.99 / month including VAT.
|Market Capitalization||4.277.161.984,00 USD|
|Indices||CDAX,Prime All Share,SDAX|
|Raw Data Source||IFRS in Millionen EUR|
Description of the company
Dermapharm Holding SE engages in the healthcare and pharmaceuticals businesses primarily in Europe. It operates through Branded Pharmaceuticals and Other Healthcare Products, and Parallel Import Business segments. It develops, manufactures, and markets generic and over-the-counter (OTC)pharmaceuticals, natural remedies, and other healthcare products. It offers systemic corticoids to treat allergic reactions, skin disease, and inflammation under the Prednisolut brand; Ampho Moronal, an antifungal drug to treat mouth, throat, and gastrointestinal diseases; Solacutan to treat keratinization; Keltican to treat back pain; and Tromcardin to treat cardiac arrhythmia. It also provides Dekristol, a vitamin D compound; sikapur, a dietary supplement to enhance skin, hair, and nails; VITA aktiv B12 Direktsticks, a galenic form of vitamin B12 with protein compounds to enhance energy and performance, and combats fatigue; and vitamin D drops and silica healthcare products under the Hubner brand. In addition, it offers Panthenol Augensalbe JENAPHARM, an eye ointment; other antibiotics or corticosteroid eye ointments and drops under the Prednifluid, Dexafluid, and Oxyteracyclin-Augensalbe JENAPHARM brands; Dienovel, a hormonal oral contraceptives to prevent pregnancy and treat acne; and Lactofem, a lactic acid treatment. Further, it provides drugs to treat bone loss and cardiovascular diseases; Simagel to treat stomach ailments; Temagin pac, a pain medication; and anesthetics under the Xylocitin-loc or Procain JENAPHARM names. Additionally, it imports and sells pharmaceuticals to wholesalers and pharmacies under the axicorp brand; and offers phytopharmaceuticals, homoeopathics, cosmetics, food and body care products, nutritional supplements, and diet and medical devices. It also operates 16 sales outlets and an online shop; and provides related services. The company was founded in 1991 and is headquartered in Grünwald, Germany. The company is a subsidiary of Themis Beteiligungs-AG.